Igor Zhuravenko, MD
Internal Medicine · Brooklyn, NYNPI 1962438598
Payments from drug & device makers
Across 215 payments — averaging $69.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$11K
- Aimmune Therapeutics, Inc.$435
- AbbVie$425
- Ironwood Pharmaceuticals, Inc$347
- Amgen$249
- Scilex Pharmaceuticals Inc.$237
- plus $2K from 18 others
What the payments were for
- Speaking & faculty fees$8,55057%
- Travel & lodging$1,42710%
- Food & beverage$4,96033%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 58 | $11,480 |
| Aimmune Therapeutics, Inc. | 6 | $435 |
| AbbVie(2 entities) | 21 | $425 |
| Ironwood Pharmaceuticals, Inc | 15 | $347 |
| Amgen | 13 | $249 |
| Scilex Pharmaceuticals Inc. | 12 | $237 |
| AstraZeneca | 9 | $232 |
| Amneal Pharmaceuticals LLC | 8 | $215 |
| Lilly USA, LLC | 15 | $208 |
| Nestle Healthcare Nutrition Inc. | 10 | $191 |
| Novo Nordisk | 9 | $169 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $147 |
| Medtronic | 3 | $100 |
| E.r. Squibb & Sons, L.L.C. | 7 | $99 |
| Boehringer Ingelheim | 5 | $93 |
| Merck | 4 | $58 |
| Shield Therapeutics Inc | 2 | $48 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Kowa Pharmaceuticals America, Inc. | 3 | $41 |
| Novartis | 2 | $38 |
| Alkermes, Inc. | 1 | $27 |
| Abbott | 1 | $23 |
| Pfizer | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,943 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 157 | $186,015 |
| VascepaIcosapent Ethyl | 461 | $172,494 |
| TrulicityDulaglutide | 156 | $155,068 |
| EliquisApixaban | 173 | $123,845 |
| LinzessLinaclotide | 196 | $114,916 |
| CreonLipase/Protease/Amylase | 139 | $114,851 |
| TradjentaLinagliptin | 121 | $65,509 |
| Tresiba Flextouch U-200Insulin Degludec | 85 | $64,306 |
| JanumetSitagliptin Phos/Metformin Hcl | 104 | $62,778 |
| Dexlansoprazole DrDexlansoprazole | 274 | $47,468 |
| OzempicSemaglutide | 38 | $45,613 |
| FarxigaDapagliflozin Propanediol | 70 | $44,873 |
| Diclofenac Sodium | 157 | $43,774 |
| ProliaDenosumab | 26 | $42,756 |
| JanuviaSitagliptin Phosphate | 62 | $37,973 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon, Namzaric, Synthroid | $425 | $283,071741 claims |
| Aimmune Therapeutics, Inc.Zenpep | $435 | $186,015157 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $208 | $176,734171 claims |
| PfizerEliquis | $21 | $123,845173 claims |
| MerckJanumet, Januvia, Janumet Xr | $58 | $106,759178 claims |
| Boehringer IngelheimTradjenta, Jardiance | $93 | $71,233133 claims |
| Novo NordiskOzempic | $169 | $45,61338 claims |
| AstraZenecaFarxiga | $232 | $44,87370 claims |
| AmgenProlia | $249 | $42,75626 claims |
| Sanofi-aventis U.S. LLCMultaq | $42 | $18,37822 claims |
| NovartisExelon | $38 | $15,11223 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Uloric | $147 | $3,79413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Brooklyn
- Bruce BergerBrooklyn$3.4M
- Nelly CohenBrooklyn$2.8M
- Jorge SerjeBrooklyn$1.3M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.